Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial

OBJECTIVE: Linagliptin, a dipeptidyl peptidase-4 inhibitor, recently demonstrated cardiovascular (CV) safety versus placebo in Asians with advanced type 2 diabetes mellitus (T2DM) in the CARMELINA(®) trial. We assessed its CV safety compared with the sulfonylurea glimepiride in Asians with relativel...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Diabetol Int
Main Authors: Kadowaki, Takashi, Wang, Guang, Rosenstock, Julio, Yabe, Daisuke, Peng, Yongde, Kanasaki, Keizo, Mu, Yiming, Mattheus, Michaela, Keller, Annett, Okamura, Tomoo, Johansen, Odd Erik, Marx, Nikolaus
Formato: Artigo
Idioma:Inglês
Publicado: Springer Singapore 2020
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7790983/
https://ncbi.nlm.nih.gov/pubmed/33479584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13340-020-00447-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares